Screener
CytomX Therapeutics CTMX Short-Term Investments
Short-Term Investments at other companies
Other financials
Where this comes from
Reported directly by CytomX Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent.
The source filing: CytomX Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-337950
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $17,224 | $12,667 |
| Short-term investments | 313,056 | 124,385 |
| Restricted cash | 917 | — |
| Accounts receivable | 37,494 | 2,013 |
| Prepaid expenses and other current assets | 4,464 | 4,856 |
| Total current assets | 373,155 | 143,921 |
Item 1. Condensed Financial Statements (Unaudited)
FAQ
- What is CytomX Therapeutics's short-term investments?
- CytomX Therapeutics (CTMX) reported short-term investments of $313.06M in Q2 2026.
- How has CytomX Therapeutics's short-term investments changed year-over-year?
- CytomX Therapeutics's short-term investments increased by 187.1% year-over-year, from $109.05M to $313.06M.
- What is the long-term trend for CytomX Therapeutics's short-term investments?
- Over 5 years (2020 to 2025), CytomX Therapeutics's short-term investments has grown at a 0.0% compound annual growth rate (CAGR), from $124.26M to $124.39M.
- What does short-term investments mean?
- Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.
Ask your AI about CytomX Therapeutics's short-term investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude